Skip to main content
. 2013 Jan 31;2013:941783. doi: 10.1155/2013/941783

Table 3.

Patients characteristics at enrollment.

Study ACCESS [27] PRoFESS [28]* SCATS [29]
treatment/placebo treatment/placebo treatment/placebo
Number of patients 173/166 647/713 1017/1012
Age 68.3 (9.3)/67.8 (9.4) 66.8 (8.8)/67.1 (9.2) 70.8 (11.2)/71.0 (11.0)
Male (%) 86 (49.7)/86 (51.8) 420 (64.9)/464 (65.1) 612 (60.2)/564 (55.7)
Clinical history
 Previous stroke/TIA NA 160 (24.7)/184 (25.8) 252 (24.8)/204 (20.2)
 Atrial fibrillation NA 10 (1.6)/14 (2.0) 190 (18.7)/186 (18.4)
 Hypertension NA 453 (70.0)/503 (70.6) 676 (66.5)/670 (66.2)
 Diabetes mellitus 67 (38.7)/58 (35.0) 176 (27.2)/198 (27.8) 163 (16.0)/157 (15.5)
 Hyperlipidemia 74 (42.8)/75 (45.2) 264 (40.8)/283 (39.7) NA
 Ischemic heart disease 38 (22)/32 (19.3) 95 (14.7)/104 (14.6) NA
Time from stroke (hours) 29.9/29.7 57.6 (16.8)/57.6 (16.8) 17.6 (8.1)/17.9 (8.1)
Blood pressure (mmHg)
 Systolic 188 (20.9)/190 (19.7) 146 (16.2)/147 (16.3) 171.2 (19.0)/171.6 (19.2)
 Diastolic 99 (14.9)/99 (13.0) 84 (10.1)/84 (10.2) 90.3 (13.9)/90.6 (14.2)
Clinical severity 60.0 (30.2)/64.1 (27.5) at BI 2.9 (2.8)/3.1 (2.9) at NIHSS 40.6 (12.3)/40.5 (12.6) at SSS

*In the PRoFESS trial a subgroup analysis has been considered.

Data are n (%) or mean (SD). NA: not assessed. BI: Barthel Index; mRS: modified ranking scale; NIHSS: National Institutes of Health Stroke Scale; SSS: Scandinavian stroke scale.